Lilly, Novo dominance to continue as TD Cowen lifts 2030 GLP-1 sales forecast by 38%
TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 ...
FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
The Independent Singapore14h
Singapore biotech tycoon Huang Zhenhua’s assets frozen in US$830 million legal battle with pharma giant
SINGAPORE: Pharmaceutical giant Novo Nordisk is taking legal action in a Singapore court, seeking damages of up to US$830 ...
Nanexa AB: Nanexa publishes year-end report and Q4 report 2024
The clinical Phase I study conducted in the NEX-22 project with good results and focus on the evaluation with Novo Nordisk has provided a good starting point for 2025. Significant events during the fo ...
Why Novo Nordisk A/S (NVO) Surged On Friday?
We recently published a list of Five Chinese Firms Dominate Friday’s Top 10 Gainers. In this article, we are going to take a ...